Excalibur Management Corp Bristol Myers Squibb CO Transaction History

Excalibur Management Corp

$273 Million
Q3 2025

A detailed history of Excalibur Management Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Excalibur Management Corp holds 30,859 shares of BMY stock, worth $1.44 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

30,859

Previous 31,681 2.59%

Holding current value

$1.44 Million

Previous $1.47 Million 5.12%

% of portfolio

0.51%

Previous 0.56%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$43.31 - $48.98 $35,600 - $40,261	-822 Reduced 2.59%	30,859 $1.39 Million
Q2 2025 Aug 06, 2025	SELL	$44.12 - $59.6 $45,928 - $62,043	-1,041 Reduced 3.18%	31,681 $1.47 Million
Q1 2025 May 08, 2025	BUY	$53.9 - $63.11 $14,714 - $17,229	273 Added 0.84%	32,722 $2 Million
Q4 2024 Feb 11, 2025	SELL	$51.92 - $59.94 $21,287 - $24,575	-410 Reduced 1.25%	32,449 $1.84 Million
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $48,305 - $63,031	1,218 Added 3.85%	32,859 $1.7 Million

Q2 2024 Aug 09, 2024	BUY	$40.25 - $52.99 $249,509 - $328,485	6,199 Added 24.37%	31,641 $1.31 Million
Q1 2024 May 13, 2024	BUY	$47.98 - $54.4 $159,245 - $180,553	3,319 Added 15.0%	25,442 $1.38 Million
Q4 2023 Feb 12, 2024	BUY	$48.48 - $57.85 $52,649 - $62,825	1,086 Added 5.16%	22,123 $1.14 Million
Q3 2023 Nov 09, 2023	BUY	$57.89 - $64.73 $67,210 - $75,151	1,161 Added 5.84%	21,037 $1.22 Million
Q2 2023 Aug 08, 2023	BUY	$63.71 - $70.74 $3,504 - $3,890	55 Added 0.28%	19,876 $1.27 Million
Q1 2023 May 05, 2023	BUY	$65.71 - $74.53 $20,238 - $22,955	308 Added 1.58%	19,821 $1.37 Million
Q4 2022 Feb 10, 2023	SELL	$68.48 - $81.09 $40,266 - $47,680	-588 Reduced 2.93%	19,513 $1.4 Million
Q3 2022 Nov 04, 2022	BUY	$0.13 - $76.84 $1 - $998	13 Added 0.06%	20,101 $1.43 Million
Q2 2022 Jul 25, 2022	SELL	$72.62 - $79.98 $278,352 - $306,563	-3,833 Reduced 16.02%	20,088 $1.55 Million
Q1 2022 May 03, 2022	SELL	$61.48 - $73.72 $5,594 - $6,708	-91 Reduced 0.38%	23,921 $1.75 Million
Q4 2021 Feb 10, 2022	BUY	$53.63 - $62.52 $202,989 - $236,638	3,785 Added 18.71%	24,012 $1.5 Million
Q3 2021 Oct 28, 2021	BUY	$59.17 - $69.31 $75,145 - $88,023	1,270 Added 6.7%	20,227 $1.2 Million
Q2 2021 Jul 26, 2021	BUY	$61.91 - $67.42 $12,382 - $13,484	200 Added 1.07%	18,957 $1.27 Million
Q1 2021 May 03, 2021	BUY	$59.34 - $66.74 $53,287 - $59,932	898 Added 5.03%	18,757 $1.18 Million
Q4 2020 Jan 26, 2021	BUY	$57.74 - $65.43 $24,424 - $27,676	423 Added 2.43%	17,859 $1.11 Million
Q3 2020 Nov 02, 2020	SELL	$57.43 - $63.64 $9,533 - $10,564	-166 Reduced 0.94%	17,436 $1.05 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $13,430 - $15,702	-245 Reduced 1.37%	17,602 $1.04 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $7,099 - $10,316	153 Added 0.86%	17,847 $995,000
Q4 2019 Feb 04, 2020	BUY	$49.21 - $64.19 $11,318 - $14,763	230 Added 1.32%	17,694 $1.14 Million
Q3 2019 Oct 21, 2019	BUY	$42.77 - $50.71 $12,103 - $14,350	283 Added 1.65%	17,464 $886,000
Q2 2019 Jul 26, 2019	BUY	$44.62 - $49.34 $64,520 - $71,345	1,446 Added 9.19%	17,181 $779,000
Q1 2019 Apr 24, 2019	SELL	$45.12 - $53.8 $451 - $538	-10 Reduced 0.06%	15,735 $751,000
Q4 2018 Jan 29, 2019	SELL	$48.76 - $63.23 $38,032 - $49,319	-780 Reduced 4.72%	15,745 $818,000
Q3 2018 Oct 25, 2018	SELL	$55.19 - $62.25 $30,354 - $34,237	-550 Reduced 3.22%	16,525 $1.03 Million
Q1 2018 Apr 23, 2018	SELL	$59.92 - $68.98 $8,988 - $10,347	-150 Reduced 0.87%	17,075 $1.08 Million
Q4 2017 Jan 22, 2018	SELL	$59.94 - $65.35 $32,367 - $35,289	-540 Reduced 3.04%	17,225 $1.06 Million
Q3 2017 Oct 25, 2017	BUY	$55.23 - $63.74 $981,160 - $1.13 Million	17,765	17,765 $1.13 Million

Others Institutions Holding BMY

# of Institutions

2,684

Shares Held

1.58B

Call Options Held

28M

Put Options Held

28.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Excalibur Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Excalibur Management Corp with notifications on news.

Account

Excalibur Management Corp Bristol Myers Squibb CO Transaction History